Project Details
Short title | ROMICAR: Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma |
---|---|
Status | Finished |
Effective start/end date | 1/08/15 → 31/08/22 |
Funding
- ONYX PHARMACEUTICALS INC
- BLOODWISE
- CELGENE INTERNATIONAL II SARL